|
Product cited in:
|
Mándoky, Géczi, Bodrogi, Tóth, Csuka, Kásler, Bak: "Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." in: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, 2004 (PubMed).
Contreras, Cobos, Lox: "Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?" in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 10, Issue 3, pp. 271-6, 2004 (PubMed).
Stephens, Hunter, Bignell, Edkins, Davies, Teague, Stevens, OMeara, Smith, Parker, Barthorpe, Blow, Brackenbury, Butler, Clarke, Cole, Dicks, Dike, Drozd, Edwards, Forbes, Foster, Gray, Greenman et al.: "Lung cancer: intragenic ERBB2 kinase mutations in tumours. ..." in: Nature, Vol. 431, Issue 7008, pp. 525-6, 2004 (PubMed).
Wang, Lien, Xia, Chen, Lo, Wang, Ali-Seyed, Lee, Bartholomeusz, Ou-Yang, Giri, Hung: "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2." in: Cancer cell, Vol. 6, Issue 3, pp. 251-61, 2004 (PubMed).
Menendez, Vellon, Mehmi, Oza, Ropero, Colomer, Lupu: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10715-20, 2004 (PubMed).
|